How Does Besivance Work? Mechanism of Action Explained in Plain English

Besivance (besifloxacin 0.6% ophthalmic suspension) is a fourth-generation fluoroquinolone antibiotic. If you've ever wondered exactly how it works — how a few drops in your eye can kill bacteria causing a pink eye infection — this plain-English explanation covers the science behind Besivance's mechanism of action, what makes it different from older eye drop antibiotics, and why it works so effectively against a broad range of bacteria.

What Class of Drug Is Besivance?

Besifloxacin belongs to the fluoroquinolone class of antibiotics — specifically, the fourth generation. Fluoroquinolones are broad-spectrum antibiotics that work differently from other antibiotics like penicillins or tetracyclines. While those classes interfere with cell wall construction or protein synthesis, fluoroquinolones target bacteria's DNA replication machinery directly.

The Core Mechanism: Targeting Two Bacterial Enzymes

Besifloxacin kills bacteria by simultaneously blocking two critical enzymes:

DNA gyrase (topoisomerase II): This enzyme is essential for unwinding DNA so it can be replicated and repaired. Without it, bacteria cannot copy their genetic material or fix damaged DNA.

Topoisomerase IV: This enzyme is needed to separate replicated DNA strands so they can be distributed to daughter cells during bacterial division. Without topoisomerase IV, bacteria cannot divide.

When besifloxacin blocks both enzymes simultaneously, it creates a state where bacterial DNA is essentially broken apart with no way to repair itself. The result: the bacteria die rapidly. This is why besifloxacin is described as bactericidal (kills bacteria outright), not merely bacteriostatic (slows growth).

Why the Dual-Target Approach Matters for Resistance

Older fluoroquinolones like ciprofloxacin primarily targeted DNA gyrase, with secondary activity against topoisomerase IV. This meant that a single mutation in the DNA gyrase gene could confer significant resistance. With besifloxacin, however, the activity against both enzymes is relatively balanced. For bacteria to become resistant, they would need to develop simultaneous mutations in both targets — a much less likely scenario than a single mutation.

This is the theoretical "dual-target" resistance advantage of fourth-generation fluoroquinolones like besifloxacin.

Why Besifloxacin Is Different from Other Fluoroquinolones

Besifloxacin has a unique distinction among fluoroquinolones: it was developed exclusively for ophthalmic use. It has no oral or IV formulation and is not used systemically. This matters because:

Common ocular pathogens have not been exposed to besifloxacin through systemic antibiotic use in other infections, preserving its susceptibility profile.

There is less cross-resistance concern compared to systemic fluoroquinolones (like oral ciprofloxacin or levofloxacin), which are widely used and have contributed to widespread fluoroquinolone resistance in many bacterial species.

The Role of DuraSite in Drug Delivery

Beyond the antibacterial mechanism, Besivance's effectiveness is also supported by its DuraSite delivery technology. DuraSite is a mucoadhesive polymer (polycarbophil) that causes the suspension to adhere to the ocular surface after instillation. This:

Extends besifloxacin's contact time with the conjunctival surface to up to 12 hours per dose

Enables effective three-times-daily dosing that maintains sustained antibacterial concentrations

Results in the characteristic gray-white appearance and temporary blurred vision briefly after instillation — a normal expected effect

Gram-Positive and Gram-Negative Coverage

Besifloxacin's dual-enzyme inhibition provides broad-spectrum coverage against both Gram-positive and Gram-negative bacteria — the two major bacterial categories. Key coverage includes:

Gram-positive: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and several other Staphylococcal and Streptococcal species

Gram-negative: Haemophilus influenzae, Moraxella catarrhalis, Moraxella lacunata, Pseudomonas aeruginosa

The Bottom Line

Besivance kills bacteria by simultaneously inhibiting two DNA replication enzymes — a mechanism that provides broad-spectrum coverage and a theoretically lower resistance risk than older antibiotics. The DuraSite formulation amplifies this by keeping the drug on the eye for extended periods. For a broader overview of Besivance, see our guide on what Besivance is and how to use it.